1. bookVolume 26 (2018): Issue 4 (October 2018)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania

Published Online: 29 Oct 2018
Volume & Issue: Volume 26 (2018) - Issue 4 (October 2018)
Page range: 443 - 449
Received: 21 May 2018
Accepted: 10 Jul 2018
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Background: Severe complications of chronic hepatitis C – i.e. cirrhosis and hepatocellular carcinoma – are important causes of morbidity and mortality worldwide. Despite the overwhelming rates of sustained virologic response achieved after therapy with different combinations of direct-acting antiviral drugs (DAAs), treatment failure is still recorded, and is due to the mutations harboured by hepatitis C virus (HCV) resistance associated variants (RAVs) selected during therapy. Baseline RAVs testing was found significant for guiding treatment in the cases of treatment failure and, sometimes, in naïve patients.

Methods: Romanian chronic hepatitis C patients unexposed to DAAs and infected with subtype 1b HCV were studied. Serum samples were used for Sanger population sequencing of a fragment containing NS3 viral protease, known to harbour resistance mutation against protease inhibitors (PIs).

Results: Catalytic triad and zinc-binding site in the studied sequences were conserved. Low-intermediate resistance mutations to first generation PIs were detected either alone or in conjunction with resistance substitutions associated with second generation PIs. Cross-resistance and reduced susceptibility to certain DAAs were observed.

Discussion: This study focused on HCV patients infected with subtype 1b strains, the most prevalent in Romania. The rate of RAVs found in this work is consistent with the results reported by similar studies from other countries. Noticeably, numerous polymorphisms of unknown significance to DAAs resistance, but reflecting the high genetic variability of HCV, were found in the studied sequences. Testing for RAVs can be a useful method for guiding treatment in a cost-efficient manner in developing countries where access to DAAs is limited.

Keywords

1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52. DOI: 10.7150/ijms.3.4710.7150/ijms.3.47Open DOISearch in Google Scholar

2. Fields BN, Knipe DM, Howley PM. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2007.Search in Google Scholar

3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318-27. DOI: 10.1002/hep.2674410.1002/hep.26744Open DOISearch in Google Scholar

4. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol. 2017;98(1):2-3. DOI: 10.1099/jgv.0.00067210.1099/jgv.0.000672Open DOISearch in Google Scholar

5. Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol. 2016;97(11):2894-907. DOI: 10.1099/jgv.0.00061210.1099/jgv.0.000612Open DOISearch in Google Scholar

6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-24. DOI: 10.1056/NEJMoa101446310.1056/NEJMoa1014463Open DOISearch in Google Scholar

7. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206. DOI: 10.1056/NEJMoa101049410.1056/NEJMoa1010494Open DOISearch in Google Scholar

8. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199-236. DOI: 10.1016/j.jhep.2015.03.02510.1016/j.jhep.2015.03.025Search in Google Scholar

9. Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, et al. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. Antiviral Res. 2014;105:112-7. DOI: 10.1016/j.antiviral.2014.02.01910.1016/j.antiviral.2014.02.019Open DOISearch in Google Scholar

10. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486-504. DOI: 10.1016/j.jhep.2015.09.01110.1016/j.jhep.2015.09.011Search in Google Scholar

11. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015. DOI: 10.1016/S0140-6736(15)60159-310.1016/S0140-6736(15)60159-3Open DOISearch in Google Scholar

12. Gheorghe L, Iacob S, Simionov I, Caruntu F, Motoc A, Arama V, et al. A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis. J Gastrointestin Liver Dis. 2014;23(1):45-50.10.15403/jgld-1278Search in Google Scholar

13. Oprisan G, Dinu S, Micu L, Micu G, Ecobici M, Spandole S, et al. Study of genetic and viral markers associated with nonresponse to triple therapy for patients with genotype 1 chronic hepatitis C. International Conference “Education and creativity for a knowledge-based society”, November 17-19, 2016. Bucharest.Search in Google Scholar

14. Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, et al. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 2018;150:9-14. DOI: 10.1016/j.antiviral.2017.12.00110.1016/j.antiviral.2017.12.00129217468Open DOISearch in Google Scholar

15. Nițescu M, Vâjâitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preoțescu L, et al. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. Rev Romana Med Lab. 2017;25(4):355-63. DOI: 10.1515/rrlm-2017-003010.1515/rrlm-2017-0030Open DOISearch in Google Scholar

16. Sultana C, Oprisan G, Szmal C, Vagu C, Temereanca A, Dinu S, et al. Molecular epidemiology of hepatitis C virus strains from Romania. J Gastrointestin Liver Dis. 2011;20(3):261-6.Search in Google Scholar

17. Sultana C, Oprisan G, Teleman MD, Dinu S, Oprea C, Voiculescu M, et al. Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol. 2016;22(37):8406-13. DOI: 10.3748/wjg.v22.i37.840610.3748/wjg.v22.i37.8406505587127729747Open DOISearch in Google Scholar

18. Dinu S, Calistru PI, Ceausu E, Tardei G, Oprisan G. Screening of Protease Inhibitors Resistance Mutations in Hepatitis C Virus Isolates Infecting Romanian Patients Unexposed to Triple Therapy. Roum Arch Microbiol Immunol. 2015;74(1-2):7-17.Search in Google Scholar

19. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999;41:95-8.Search in Google Scholar

20. Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, et al. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PloS One. 2016;11(5):e0155869. DOI: 10.1371/journal.pone.015586910.1371/journal.pone.0155869487322027196673Search in Google Scholar

21. Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38 Suppl 1:7-13. DOI: 10.1111/liv.1367310.1111/liv.13673771351429427484Open DOISearch in Google Scholar

22. Bagaglio S, Uberti-Foppa C, Morsica G. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017;77(10):1043-55. DOI: 10.1007/s40265-017-0753-x10.1007/s40265-017-0753-x28497432Search in Google Scholar

23. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Apr 9. pii:S0168-8278(18)31968-8.Search in Google Scholar

24. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016;151(1):70-86. DOI: 10.1053/j.gastro.2016.04.00310.1053/j.gastro.2016.04.00327080301Open DOISearch in Google Scholar

25. Vidal LL, Soares MA, Santos AF. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. J Viral Hepat. 2016;23(11):840-849. DOI: 10.1111/jvh.1250310.1111/jvh.1250326775769Open DOISearch in Google Scholar

26. Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910-7. DOI: 10.3748/wjg.v22.i40.891010.3748/wjg.v22.i40.8910508379627833382Open DOISearch in Google Scholar

27. Sargin Altunok E, Sayan M, Akhan S, Aygen B, Yildiz O, Tekin Koruk S, et al. Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. Int J Infect Dis. 2016;50:1-5. DOI: 10.1016/j.ijid.2016.07.00310.1016/j.ijid.2016.07.003Open DOISearch in Google Scholar

28. Echeverria N, Betancour G, Gambaro F, Hernandez N, Lopez P, Chiodi D, et al. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries. Virus Res. 2016;223:140-6. DOI: 10.1016/j.virusres.2016.07.00810.1016/j.virusres.2016.07.008Open DOISearch in Google Scholar

29. Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14(6):229-37. DOI: 10.1007/s11904-017-0369-510.1007/s11904-017-0369-5Open DOISearch in Google Scholar

30. Chevaliez S, Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S31-41. DOI: 10.1016/S2210-7401(11)70005-510.1016/S2210-7401(11)70005-5Open DOISearch in Google Scholar

31. Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. DOI: 10.1038/srep2031010.1038/srep20310Open DOISearch in Google Scholar

32. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 1996;87(2):331-42. DOI: 10.1016/S0092-8674(00)81350-110.1016/S0092-8674(00)81350-1Open DOISearch in Google Scholar

33. Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z. The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol. 1997;71(4):2881-6.10.1128/jvi.71.4.2881-2886.19971914149060645Search in Google Scholar

34. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PloS One. 2015;10(8):e0134395. DOI: 10.1371/journal.pone.013439510.1371/journal.pone.0134395455268626317755Search in Google Scholar

35. Zhou K, Liang Z, Wang C, Hu F, Ning C, Lan Y, et al. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naive HIV/HCV Co-Infected Patients in China. PloS One. 2016;11(6):e0157438. DOI: 10.1371/journal.pone.015743810.1371/journal.pone.0157438492040227341031Search in Google Scholar

36. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, et al. Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-acting Antivirals. Gastroenterology. 2017;154(4):976-988.e4. DOI: 10.1053/j.gastro.2017.11.00710.1053/j.gastro.2017.11.00729146520Open DOISearch in Google Scholar

37. Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, et al. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2017;52(1):94-103. DOI: 10.1007/s00535-016-1225-x10.1007/s00535-016-1225-x27236547Open DOISearch in Google Scholar

38. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50(6):1709-18. DOI: 10.1002/hep.2319210.1002/hep.2319219787809Open DOISearch in Google Scholar

39. Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol. 2015;65:50-3. DOI: 10.1016/j.jcv.2015.02.00510.1016/j.jcv.2015.02.005472829825766988Open DOISearch in Google Scholar

40. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013;444(1-2):329-36. DOI: 10.1016/j.virol.2013.06.02910.1016/j.virol.2013.06.02923876458Open DOISearch in Google Scholar

41. Fourati S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. Viruses. 2015;7(12):6346-59. DOI: 10.3390/v712294110.3390/v7122941469086526690198Open DOISearch in Google Scholar

42. Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, et al. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. J Clin Microbiol. 2016;54(10):2470-84. DOI: 10.1128/JCM.00330-1610.1128/JCM.00330-16503540727385709Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo